Experts highlight the potential of under-utilised treatments like monoamine oxidase inhibitors while examining emerging ...

I liked DOOM: House of Hope, German artist Anne Imhof’s hotly anticipated but now widely panned immersive-performance ...

Ketamine has promise as a potential treatment for bipolar depression, particularly for people whose condition hasn’t ...

J&J is already seeing strong sales growth for its treatment-resistant depression (TRD) and MDD therapy Spravato (esketamine), ...

Johnson & Johnson (J&J) is dropping its Phase III major depressive disorder (MDD) programme for aticaprant due to ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

A receptor that cannabis latches onto in the brain could be a promising target for future mental health treatments.

Children too can have mental health issues! Parents should take note of these subtle signs of compromised mental health in ...

Johnson & Johnson is ending the phase 3 VENTURA clinical development program evaluating aticaprant, a selective kappa receptor antagonist, as an adjunctive treatment for major depressive disorder (MDD ...

Every relationship has its seasons. The warm, sunny days of early romance eventually give way to different weather patterns, ...